Isomorphic Labs raises $5B as AI drug design engine posts positive preclinical cancer results
kimmonismus · x · 2026-11-17
Demis Hassabis's Isomorphic Labs announced a $5 billion Series C co-led by Greenoaks and Sequoia Capital, with a16z joining and Alphabet investing further; all existing investors including Thrive, MGX, GV, and Temasek participated.
The company says its proprietary drug design engine IsoDDE, paired with agents that navigate and reason over complex biological systems, is already delivering positive preclinical results in internal oncology and immunology programs as well as partner projects, setting the stage for clinical trials. New capital will scale IsoDDE, build AI-first translational and clinical development infrastructure, and construct global compute for AI-led bioengineering.
Related event: Isomorphic Labs Raises $5 Billion to Pursue AI-Driven Drug Discovery(7 posts)→
More from AGI Musings
- Jarovsky: Those profiting from dangerous AI will never admit it's unsafe — LuizaJarovsky · 2026-11-17
- Gary Marcus mocks the ASI race: 'we're already in a mountain of shit' — GaryMarcus · 2026-11-17
- Ethan Mollick on the AI bull case: the expected value is just continued 2% growth — emollick · 2026-11-17
- Why the experiment matters: do agents pick the best tools, or do we still need verification? — santiviquez · 2026-11-17
- "Are all Reddit posts just AI now?" — users say everything reads like Claude — adonis_singh · 2026-11-17
- Beach birdwatching sparks an AI analogy: small focused models beat do-everything LLMs — shashib · 2026-11-17